Revance Therapeutics Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Employees
-
675
- Latest Deal Type
-
Buyout/LBO
- Financing Rounds
-
17
- Investments
-
3
Revance Therapeutics General Information
Description
Developer of botulinum toxin products intended to be used in aesthetic and therapeutic applications. The company specializes in healthcare with innovative aesthetic and therapeutic offerings, thereby helping physicians, patients, and consumers enhance their outcomes and experiences significantly.
Contact Information
Website
www.revance.com(Operating Subsidiary)
Corporate Office
- 1222 Demonbreun Street
- 20th Floor
- Nashville, TN 37203
- United States
Corporate Office
- 1222 Demonbreun Street
- 20th Floor
- Nashville, TN 37203
- United States
Revance Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Revance Therapeutics Comparisons
Industry
Financing
Details
Revance Therapeutics Competitors (27)
One of Revance Therapeutics’s 27 competitors is Meditope Biosciences, a Formerly VC-backed company based in Pasadena, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Meditope Biosciences | Formerly VC-backed | Pasadena, CA | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| PhoreMost | Venture Capital-Backed | Cambridge, United Kingdom | ||||
| Agenus | Formerly VC-backed | Lexington, MA | ||||
| CytomX Therapeutics | Formerly VC-backed | South San Francisco, CA |
Revance Therapeutics Signals
Revance Therapeutics Former Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Revance Therapeutics Investments & Acquisitions (3)
Revance Therapeutics’s most recent deal was a Merger/Acquisition with HintMD for . The deal was made on 23-Jul-2020.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| HintMD | 23-Jul-2020 | Merger/Acquisition | Other Healthcare Services | ||
| Inner Resource | 13-Feb-2019 | Early Stage VC | Business/Productivity Software | ||
| Botulinum Toxin Research Associates (Botulinum Toxin Patent Portfolio) | 02-Jun-2016 | Corporate Asset Purchase | Buildings and Property |
Revance Therapeutics FAQs
-
When was Revance Therapeutics founded?
Revance Therapeutics was founded in 1999.
-
Where is Revance Therapeutics headquartered?
Revance Therapeutics is headquartered in Nashville, TN.
-
What is the size of Revance Therapeutics?
Revance Therapeutics has 675 total employees.
-
What industry is Revance Therapeutics in?
Revance Therapeutics’s primary industry is Drug Discovery.
-
Is Revance Therapeutics a private or public company?
Revance Therapeutics is a Private company.
-
What is the current valuation of Revance Therapeutics?
The current valuation of Revance Therapeutics is .
-
What is Revance Therapeutics’s current revenue?
The current revenue for Revance Therapeutics is .
-
How much funding has Revance Therapeutics raised over time?
Revance Therapeutics has raised $921M.
-
Who are Revance Therapeutics’s investors?
Bio*One Capital, , Brown Brothers Harriman, CNF Investments, and Delphi Ventures (California) are 5 of 17 investors who have invested in Revance Therapeutics.
-
Who are Revance Therapeutics’s competitors?
Meditope Biosciences, Genentech, PhoreMost, Agenus, and CytomX Therapeutics are some of the 27 competitors of Revance Therapeutics.
-
When was Revance Therapeutics acquired?
Revance Therapeutics was acquired on 06-Feb-2025.
-
Who acquired Revance Therapeutics?
Revance Therapeutics was acquired by Crown Laboratories.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process